Osvaren (Magnesium Carbonate Heavy, Calcium Acetate)

Magnesium carbonate heavy, the active ingredient in Osvaren, is a phosphate binder presented as a oral formulation for gastrointestinal use. It treats hyperphosphatemia in patients with chronic kidney disease undergoing dialysis. Calcium acetate, the second active ingredient, is also a phosphate binder used for the same purpose.

GNH USA supplies Osvaren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and dialysis clinics worldwide.

Osvaren is a phosphate‑binding medication used in the management of disorders that involve elevated serum phosphate levels. - Chronic kidney disease (CKD) on dialysis: helps lower serum phosphate to target ranges recommended by nephrology guidelines. - Hyperphosphatemia secondary to renal failure: reduces phosphate absorption from the diet. - Adjunct to dietary phosphate restriction: enhances the effectiveness of low‑phosphate diets in maintaining mineral balance.

Osvaren may cause a range of adverse reactions, most of which are related to its mineral content and gastrointestinal activity.

Common Side Effects: - Diarrhea: loose stools, often mild to moderate. - Constipation: reduced bowel movements, occasionally due to excess binding. - Nausea: feeling of queasiness, typically transient. - Abdominal discomfort: cramping or bloating. - Hypermagnesemia: elevated magnesium levels, usually mild. - Hypercalcemia: elevated calcium levels, especially with high doses.

Serious or Rare Side Effects: - Severe hypermagnesemia: can lead to muscle weakness, respiratory depression, or cardiac arrhythmias. - Severe hypercalcemia: may cause renal stones, vascular calcification, or cardiac rhythm disturbances. - Metabolic alkalosis: rare shift in acid‑base balance. - Allergic reactions: rash, itching, or anaphylaxis in hypersensitive individuals.

When prescribing Osvaren, clinicians should consider several safety aspects to minimize risks. - Monitor serum phosphate: adjust dose to maintain target levels. - Check calcium and magnesium levels: avoid hypercalcemia or hypermagnesemia. - Assess renal function: dose may need modification in residual kidney function. - Review concomitant phosphate binders: avoid excessive mineral load. - Evaluate gastrointestinal tolerance: consider alternative binders if severe diarrhea or constipation occurs. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight.

Osvaren can interact with other medicines that affect mineral balance or gastrointestinal absorption.

Major Interactions (Avoid): - Oral iron supplements: phosphate binding may reduce iron absorption; separate administration by at least 2 hours. - Tetracycline antibiotics: chelation can diminish antibiotic efficacy; separate dosing. - Bisphosphonates: concurrent use may impair phosphate‑binding capacity; avoid co‑administration.

Moderate Interactions (Monitor Closely): - Vitamin D analogues: may increase calcium absorption, raising hypercalcemia risk. - Loop diuretics: can alter calcium excretion, requiring electrolyte monitoring. - Proton‑pump inhibitors: may change gastric pH and affect binder solubility. - Antacids containing aluminum or magnesium: additive mineral load may need dose adjustment.